NPS Pharmaceuticals price target raised to $41 from $36 at Brean Capital Brean Capital raised its price target on NPS Pharmaceuticals following yesterday's 2014 guidance. The firm believes its guidance is conservative and it will beat and raise its guidance over the course of the year. Shares are Buy rated.
News For NPSP From The Last 14 Days
Check below for free stories on NPSP the last two weeks.